Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).

Ashish SharmaFrank G HolzCarl D RegilloK Bailey FreundDavid SarrafArshad M KhananiCaroline BaumalNancy M HolekampRamin TadayoniNilesh KumarNikulaa ParachuriBaruch D Kuppermannnull null

Published in: Expert opinion on biological therapy (2023)

The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.

Keyphrases

primary care
optical coherence tomography
diabetic retinopathy
cross sectional
optic nerve
healthcare
medical education